Mineralocorticoid receptor antagonists reduce risk of cardiovascular events in patients with heart failure
MRAs significantly lower the risk of cardiovascular death and HF hospitalization in heart failure patients.
MRAs significantly lower the risk of cardiovascular death and HF hospitalization in heart failure patients.